Skip to main content

Security report for marcanpharma.com

Marcan Pharmaceuticals Inc. · Healthcare · Canada

Medium risk. 3 critical or high findings in GDPR outside view and SSL/TLS.

Security score

73/100

Risk levelMedium

0–100, higher is better. How it is calculated

Marcan Pharmaceuticals Inc. is a Canadian pharmaceutical company specializing in generic drugs with a growing portfolio of over 60 products distributed across more than 12,500 pharmacies nationwide. The company focuses on quality, patient access, and supply reliability, positioning itself as a rapidly expanding player in the Canadian pharmaceutical market. Their product range includes both oral and injectable medications, targeting healthcare providers and patients across Canada. Technically, the website is built on the Webflow platform, leveraging modern web technologies such as Google Analytics, Google Tag Manager, Weglot for multilingual support, and jQuery. The site is mobile-optimized with good SEO practices and basic accessibility features. Performance is moderate with embedded multimedia content enhancing user engagement. From a security perspective, the site uses HTTPS with no visible vulnerabilities or exposed sensitive data. Cookie consent mechanisms and privacy policies are in place, indicating compliance with GDPR. However, the absence of a published security policy, incident response contacts, and vulnerability disclosure reduces the overall security maturity. The missing WHOIS data for the domain raises concerns about domain registration legitimacy, although the professional website content suggests a legitimate business. Overall, Marcan Pharmaceuticals presents a credible and professional online presence with room for improvement in transparency around security policies and domain registration details. Strategic recommendations include publishing security and incident response policies, enhancing accessibility, and clarifying domain registration information to improve trust and compliance.

Scanned

NIS2 and GDPR posture

GDPR outside view
68/ 100 · Medium
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

3 findings rated critical or high. Fix these first.

  1. GDPR outside view

    These are the privacy signals visitors and data protection authorities look for under GDPR.

    • High

      No Cookie Consent Banner found

      GDPR requires explicit consent for non-essential cookies

      What to do: Implement a cookie consent banner that appears on first visit

  2. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1
    • High

      Weak SSL Key Length

      SSL certificate uses 256-bit key, which is considered weak

      What to do: Use at least 2048-bit RSA or 256-bit ECC key

      • CWE-326
      • OWASP A04:2025
      • Mozilla TLS: Mozilla Server Side TLS 6.0 intermediate: rsa_key_size 2048

Need hands-on remediation? Email guard@offseq.com

Keep watching marcanpharma.com

This scan found 20 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. See sample alerts.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
57
Security headers
60
Email security
70
DNS health
85
Network security
100
GDPR outside view
68
Average
73

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Marcan Pharmaceuticals operates in the Canadian healthcare sector as a generic pharmaceutical manufacturer and distributor. Their competitive advantage lies in a broad product portfolio and extensive distribution network covering retail and hospital pharmacies nationwide. The business model focuses on product development, marketing, and sales within Canada, targeting pharmacies and patients. Growth indicators include recent product launches and hiring announcements for regulatory affairs specialists, signaling expansion and compliance focus. The company maintains a LinkedIn presence for professional engagement but lacks visible partnerships or subsidiaries on the website. The absence of WHOIS data is a notable anomaly that should be addressed to reinforce legitimacy and trust.

Security posture

The website demonstrates a moderate security posture with HTTPS enforced and cookie consent implemented. No security headers were detected in the provided data, and there is no published security policy or incident response information, which are gaps in security transparency. No vulnerabilities or exposed sensitive data were found in the HTML content. The lack of a vulnerability disclosure or security.txt file limits the ability for external security researchers to report issues. Overall, the security maturity is adequate for a corporate website but could be improved by adding formal security documentation and enhancing HTTP security headers.

Recommendations

  1. Publish a dedicated security policy and incident response page to improve transparency and preparedness.
  2. Implement and publish a vulnerability disclosure policy or security.txt file to facilitate responsible reporting.
  3. Enhance HTTP security headers such as Content-Security-Policy, X-Frame-Options, and Strict-Transport-Security.
  4. Improve website accessibility features to meet higher standards and broaden user inclusivity.
  5. Clarify domain registration details and ensure WHOIS data is available to strengthen domain legitimacy and trust.

Contact details published on the site

Addresses
Legal name
Marcan Pharmaceuticals Inc.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Marcan Pharmaceuticals Inc.
Description
Marcan Pharmaceuticals Inc. is one of the fastest-growing generic pharmaceutical companies in Canada with products in over 12500 pharmacies in every province and territory of Canada. They offer over 60 pharmaceutical drugs including orals and injectables, focusing on quality, patient access, and supply. The company is Ottawa based and engaged in development, marketing, sales, and distribution of brand and generic pharmaceutical products for the Canadian market.
Key services
Development of pharmaceutical products, Marketing and sales, Distribution to retail and hospital pharmacies
Content quality
good
Branding
consistent

Technology

Stack
Google Analytics, Google Tag Manager, jQuery, Typed.js, Weglot (translation), Webflow CMS
Frameworks
Webflow
Platforms
YouTube (embedded video)
Performance
moderate
Mobile
good
Accessibility
basic
SEO
good

Security

Observed score
80/100
Good practices seen
  • HTTPS enabled
  • Cookie consent mechanism
  • No exposed sensitive data in HTML

Analytics and tracking

Services
Google Analytics, Google Tag Manager
Tracking level
moderate
Privacy practices
good

Advertising

Marketing tools
Weglot translation
Transparency
basic

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is fully accessible with no blocking or WAF challenge.
  2. WHOIS data is missing or unavailable, which is unusual for a .com domain.
  3. Website uses modern web technologies and analytics tools.
  4. Privacy and cookie policies are present and GDPR compliant.
  5. No explicit security policy or incident response information found.
  6. No contact emails or phone numbers explicitly listed on homepage or footer.
  7. Physical address is provided in footer.
  8. Social media presence limited to LinkedIn.
  9. No terms of service page detected.
  10. Content is relevant and professional for pharmaceutical industry.
Technical notes

Notes

The website is built on the Webflow CMS platform, utilizing modern JavaScript libraries including jQuery and Typed.js for UI enhancements. Google Analytics and Google Tag Manager are used for tracking and marketing analytics. Weglot provides multilingual support, indicating an internationalization strategy. The site embeds YouTube videos for brand messaging. Performance is moderate with asynchronous loading of scripts and CDN usage for assets. The site is mobile responsive with good SEO metadata and structured navigation. However, there is no detected hosting provider information or advanced backend technologies visible from the front-end data. Technical risks are low but could be mitigated by improving security headers and accessibility compliance.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with marcanpharma.com. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review marcanpharma.com.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.